BCL2 and acute lymphoblastic leukemia: Nevertheless, reliable upfront identification of patients who would potentially benefit from strategies targeting BCL-2 is mandatory for decision-making and therapy guidance of individual patients in future evaluation and clinical application of VEN in ALL patients.